Iris H C Miedema
Overview
Explore the profile of Iris H C Miedema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michelet R, Petersson K, Huisman M, Menke-van der Houven van Oordt C, Miedema I, Thiele A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Dec;
PMID: 39654382
In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)-imaging is a promising noninvasive method to...
2.
Muijlwijk T, Wondergem N, Ekhlas F, Remkes N, Nijenhuis D, Fritz L, et al.
Cancer Immunol Immunother
. 2024 Sep;
73(11):229.
PMID: 39249543
Immune checkpoint inhibitors are approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) but the response rate is only 13-18%. For an effective antitumor immune response, trafficking of immune...
3.
Wondergem N, Miedema I, van de Ven R, Zwezerijnen G, de Graaf P, Karagozoglu K, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 39038919
Background: Addition of neoadjuvant immune checkpoint inhibition to standard-of-care interventions for locally advanced oral cancer could improve clinical outcome. Methods: In this study, 16 evaluable patients with stage III/IV oral...
4.
Miedema I, Pouw J, Kwakman A, Zwezerijnen G, Huisman M, Timmer F, et al.
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38886117
Introduction: Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using F-BMS-986192...
5.
Miedema I, Wijngaarden J, Pouw J, Zwezerijnen G, Sebus H, Smit E, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067257
Introduction: Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([Zr]Zr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune system. The measured uptake consists of target-specific and...
6.
Miedema I, Huisman M, Zwezerijnen G, Grempler R, Perez Pitarch A, Thiele A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Mar;
50(7):2068-2080.
PMID: 36859619
Purpose: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the...
7.
Rijcken C, De Lorenzi F, Biancacci I, Hanssen R, Thewissen M, Hu Q, et al.
Adv Drug Deliv Rev
. 2022 Nov;
191:114613.
PMID: 36343757
Nanomedicines are used to improve the efficacy and safety of pharmacotherapeutic interventions. Unraveling the biological behavior of nanomedicines, including their biodistribution and target site accumulation, is essential to establish design...
8.
Verhoeff S, van de Donk P, Aarntzen E, Oosting S, Brouwers A, Miedema I, et al.
J Nucl Med
. 2022 May;
63(10):1523-1530.
PMID: 35512998
In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study, we performed Zr-DFO-durvalumab (anti-PD-L1 [programmed death ligand 1]) PET/CT in patients with recurrent or metastatic (R/M) squamous...
9.
Miedema I, Zwezerijnen G, Huisman M, Doeleman E, Mathijssen R, Lammers T, et al.
Adv Mater
. 2022 Apr;
34(21):e2201043.
PMID: 35427430
Several FDA/EMA-approved nanomedicines have demonstrated improved pharmacokinetics and toxicity profiles compared to their conventional chemotherapeutic counterparts. The next step to increase therapeutic efficacy depends on tumor accumulation, which can be...
10.
Boni V, Fidler M, Arkenau H, Spira A, Meric-Bernstam F, Uboha N, et al.
Clin Cancer Res
. 2022 Feb;
28(10):2020-2029.
PMID: 35165101
Purpose: Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target...